DATASOURCEBYDAIICHISANKYO.COM: Keyword Density Checker

Total words: 1572 | 2-word phrases: 401 | 3-word phrases: 445 | 4-word phrases: 470

PAGE INFO

Title	Try to keep the title under 60 characters (58 characters) DataSource \| Daiichi Sankyo - DataSource by Daiichi Sankyo
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (10 characters) Navigation

#	Keyword	Frequency	Density
1	carousal item 3	2	0.45%
2	contained is subject	2	0.45%
3	datasource by daiichi	2	0.45%
4	by daiichi sankyo	2	0.45%
5	of print learn	2	0.45%
6	print learn more	2	0.45%
7	esmo gi 2024	2	0.45%
8	growth factor receptor	2	0.45%
9	previous arrow next	2	0.45%
10	the content contained	2	0.45%
11	content contained is	2	0.45%
12	includes select daiichi	2	0.45%
13	connect with an	2	0.45%
14	the information provided	2	0.45%
15	et al j	2	0.45%
16	pipeline compounds or	2	0.45%
17	compounds or investigational	2	0.45%
18	or investigational uses	2	0.45%
19	publications carousal item	2	0.45%
20	these compounds or	2	0.45%
21	compounds or uses	2	0.45%
22	epidermal growth factor	2	0.45%
23	with an msl	2	0.45%
24	arrow next arrow	2	0.45%
25	this site is	2	0.45%
26	chicago il usa	2	0.45%
27	congresses carousal item	2	0.45%
28	us healthcare professional	2	0.45%
29	a us healthcare	2	0.45%
30	carousal item 1	2	0.45%

#	Keyword	Frequency	Density
1	epidermal growth factor receptor	2	0.43%
2	compounds or investigational uses	2	0.43%
3	datasource by daiichi sankyo	2	0.43%
4	previous arrow next arrow	2	0.43%
5	content contained is subject	2	0.43%
6	the content contained is	2	0.43%
7	connect with an msl	2	0.43%
8	pipeline compounds or investigational	2	0.43%
9	of print learn more	2	0.43%
10	a us healthcare professional	2	0.43%
11	these compounds or uses	2	0.43%
12	k goto y kubo	1	0.21%
13	goto k goto y	1	0.21%
14	trial goto k goto	1	0.21%
15	destinylung02 trial goto k	1	0.21%
16	ii destinylung02 trial goto	1	0.21%
17	phase ii destinylung02 trial	1	0.21%
18	randomized phase ii destinylung02	1	0.21%
19	in patients with her2mutant	1	0.21%
20	metastatic nonsmallcell lung cancer	1	0.21%
21	primary results from the	1	0.21%
22	more trastuzumab deruxtecan in	1	0.21%
23	trastuzumab deruxtecan in patients	1	0.21%
24	deruxtecan in patients with	1	0.21%
25	cancer primary results from	1	0.21%
26	lung cancer primary results	1	0.21%
27	nonsmallcell lung cancer primary	1	0.21%
28	learn more trastuzumab deruxtecan	1	0.21%
29	kubo t et al	1	0.21%
30	goto y kubo t	1	0.21%
31	a phase ii trial	1	0.21%
32	after epidermal growth factor	1	0.21%
33	cancer after epidermal growth	1	0.21%
34	factor receptormutated nonsmallcell lung	1	0.21%
35	growth factor receptormutated nonsmallcell	1	0.21%
36	epidermal growth factor receptormutated	1	0.21%
37	in epidermal growth factor	1	0.21%
38	her3dxd in epidermal growth	1	0.21%
39	trial of patritumab deruxtecan	1	0.21%
40	ii trial of patritumab	1	0.21%

#	URL	Whois	Check
1	https://datasourcebydaiichisankyo.com/home	Whois	.
2	https://datasourcebydaiichisankyo.com/congresses	Whois	.
3	https://datasourcebydaiichisankyo.com/publications	Whois	.
4	https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13613	Whois	wiley.com
5	https://ascopubs.org/doi/10.1200/JCO.23.01361	Whois	ascopubs.org
6	https://ascopubs.org/doi/10.1200/JCO.23.01476	Whois	ascopubs.org
7	https://www.dsimedinfo.com/web/medinfo/msl	Whois	dsimedinfo.com
8	https://www.linkedin.com/company/daiichi-sankyo	Whois	linkedin.com
9	https://twitter.com/DaiichiSankyoUS?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor	Whois	twitter.com
10	https://daiichisankyo.us/terms-and-conditions	Whois	daiichisankyo.us
11	https://daiichisankyo.us/privacy-notice	Whois	daiichisankyo.us
12	https://daiichisankyo.us/contact-us	Whois	daiichisankyo.us
13	https://www.dsimedinfo.com/	Whois	dsimedinfo.com